Addition of capecitabine improves recurrence-free survival in breast cancer patients but with increased adverse events

November 09, 2009

Addition of capecitabine to a standard chemotherapy regimen for breast cancer improves recurrence-free survival. However, increased adverse events mean treatment with capecitabine is frequently discontinued. These are the findings of an Article published Online First and in the December edition of The Lancet Oncology, written by Professor Heikki Joensuu, Helsinki University Central Hospital, Finland, and colleagues.

In this randomised controlled trial, 1500 women with moderate-to-high risk early breast cancer were assigned to either three cycles of capecitabine and docetaxel followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (capecitabine group, n=753), or to three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (control group, n=747). The control combination was representative of a regimen frequently used in Finland and Sweden, and similar to the regimen administered in many other countries. The primary endpoint was recurrence-free survival. In this study, the authors carried out a planned interim analysis after 3 years' median follow-up.

The team found that recurrence-free survival at 3 years was better with the capecitabine regimen than with control (93% vs 89%). The capecitabine regimen was associated with more cases of grade 3 or 4 diarrhoea (6% vs 3%) and hand-foot syndrome* (11% vs <1%) and the control regimen with more occurrences of grade 3 or 4 neutropenia** (98% vs 86%) and febrile neutropenia (9% vs 4%). More patients discontinued planned treatment in the capecitabine group (24% vs 3% in the control arm).

The authors say: "The capecitabine-containing chemotherapy regimen reduced breast cancer recurrence compared with a control schedule of standard agents. Capecitabine administration was frequently discontinued because of adverse effects... Our results suggest that integration of capecitabine upfront with potentially synergistic chemotherapeutic agents and into several cycles might be an effective treatment strategy."

They add: "Integration of capecitabine was associated with frequent discontinuation of planned chemotherapy, but most patients could tolerate all six scheduled cycles. Studies that focus on further refinement of the current chemotherapy regimen are warranted."

In an accompanying Reflection and Reaction comment, Dr Ruth M. O'Regan. Emory Winship Cancer Institute, Atlanta, GA, USA, says: "Although the findings of this trial are not practice-changing, they are intriguing and could merit further assessment in a larger trial. However, the significant toxicity noted with the addition of capecitabine to the taxane-anthracycline backbone dampens enthusiasm for further studies of this approach. More importantly, it is imperative that we take a more rational approach to the treatment of early-stage breast cancer by tailoring our treatment approaches to molecular phenotypes."
-end-
Professor Heikki Joensuu, Helsinki University Central Hospital, Finland. T) +358 40 72 10 438 E) heikki.joensuu@hus.fi

For Dr Ruth M. O'Regan, Emory Winship Cancer Institute, Atlanta, GA, USA, please contact Vince Dollard, Communications Department. T) +1 404-778-4580 E) vdollar@emory.edu / Ruth_ORegan@emoryhealthcare.org

For full Article and Reflection and Reaction, see: http://press.thelancet.com/tlocapec.pdf

Notes to editors:

*Hand-foot syndrome is is a swelling and numbness of the hands and feet that occurs with certain types of chemotherapy.

**neutropenia is an abnormally low number of neutrophils, the most important type of white blood cell, in the blood. Febrile neutropenia is neutropenia with associated fever, often with other signs of infection.

Lancet

Related Capecitabine Articles from Brightsurf:

CNIO identifies genetic factors associated to hand-foot syndrome in chemotherapy with capecitabine
* The researchers studied more than 600,000 genetic variants in the genome of 166 patients treated with the chemotherapy drug capecitabine * Before undergoing treatment, the patients carrying the risk alleles for the hand-foot syndrome had low levels of two proteins that are key to the effective functioning of the skin barrier * The finding may help classify patients according to their genetic risk for developing this side effect of some cancer treatments

Oncotarget: Second line trastuzumab emtansine following horizontal dual blockade
Volume 11, Issue 22 of Oncotarget reported that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.

Study finds no overall survival benefit, but improved quality of life with talazoparib in advanced BRCA-mutated breast cancer
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial
A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more aggressive treatment.

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

Tucatinib 'game changing' against HER2+ breast cancer, especially with brain metastases
Phase III results at NEJM and SABCS: Adding tucatinib to standard of care treatment nearly tripled one-year progression-free survival.

NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Continuous chemotherapy improves outcomes and quality of life in advanced breast cancer
Continuous chemotherapy shows greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented at the ESMO Breast Cancer Congress 2019, May 2-4, Berlin, Germany.

AACR: Adavosertib speeds cancer cells into the wall of mitotic catastrophe
A University of Colorado Cancer Center study presented at AACR 2019 shows that inhibiting the action of Wee1 speeds cancer cells with damaged DNA through cell cycle, leading to mitotic catastrophe.

Adjuvant capecitabine did not improve outcomes for patients with early triple-negative breast cancer
Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium.

Read More: Capecitabine News and Capecitabine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.